trastuzumab + pertuzumab + capecitabine + oxaliplatin

trastuzumab + pertuzumab + capecitabine + oxaliplatin (XELOX) is an investigational neoadjuvant combination therapy being evaluated for the treatment of locally advanced HER2-positive rectal cancer. This regimen, specifically studied in the NePHera Phase II trial sponsored by Peking Union Medical College Hospital, utilizes biosimilar versions of the anti-HER2 monoclonal antibodies trastuzumab and pertuzumab in conjunction with the XELOX chemotherapy backbone. Trastuzumab and pertuzumab provide dual blockade of the HER2 receptor by binding to distinct extracellular domains (subdomain IV and II, respectively), which inhibits receptor dimerization and downstream signaling while promoting antibody-dependent cellular cytotoxicity (ADCC). The XELOX component consists of oxaliplatin, a platinum-based agent that forms DNA cross-links, and capecitabine, an oral prodrug of 5-fluorouracil that inhibits thymidylate synthase, collectively providing potent cytotoxic activity against rapidly dividing tumor cells.

Other names

trastuzumab + pertuzumab + XELOX-Peking Union Medical College Hospital-rectal cancertrastuzumab biosimilars and pertuzumab biosimilars plus XELOXtrastuzumab + pertuzumab + XELOX